A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 716 participants.
Also called NCT01106651
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 716 participants
- Registry
-
NCT01106651
-
- Other papers using this trial's data
- Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
- Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Colombia, France, Greece, Hong Kong SAR China, India, New Zealand, Poland, Romania, South Africa, Spain, Sweden, Switzerland, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01106651. Randomized; triple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2011-11 (actual). Results posted on 2013-05-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Canagliflozin 100 mg
- Intervention (Drug)
- Canagliflozin 300 mg
- Intervention (Drug)
- Antihyperglycemic agent(s)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct01106651- Content hash
eee203fc3daf7883d6969f1a7825dcfe5092354cd831b67ed219772401979f3d